Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

This pilot phase II trial studies how well pembrolizumab works in treating patients with desmoplastic melanoma (DM) that can be removed by surgery (resectable) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Official Title

A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)

Details

Keywords

Desmoplastic Melanoma, Melanoma, Pembrolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Positron Emission Tomography, pembrolizumab, surgery

Eligibility

Locations

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT02775851
Phase
Phase 2 Skin Cancer/Melanoma Research Study
Study Type
Interventional
Participants
About 57 people participating
Last Updated